Literature DB >> 23727325

Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.

A Browne1, R Sriraksa, T Guney, N Rama, S Van Noorden, E Curry, H Gabra, E Stronach, M El-Bahrawy.   

Abstract

INTRODUCTION: Ovarian Cancer is the leading cause of death from gynecological malignancy. The poor prognosis is mainly due to presentation at a late stage and poor response to therapy. Much research is needed to identify diagnostic and prognostic biomarkers as well as therapeutic targets for ovarian cancer. Interleukin-8 is expressed by many tumour types and is known to have mitogenic, motogenic and angiogenic effects on tumour cells. AIMS: The aim of this study was to investigate the expression of IL-8 and IL-8 receptors (IL-8RA and IL-8RB) in different histological subtypes of ovarian tumours, as potential prognostic biomarkers in ovarian tumours.
MATERIALS AND METHODS: Immunohitochemistry was used to study the expression of IL-8 and IL-8 receptors in 115 ovarian tumours including 21 benign tumours, 25 borderline tumours and 69 carcinomas of serous, clear cell, endometrioid and mucinous types. The correlation of expression profile, tumour type, stage, and progression free survival and overall survival was statistically analysed.
RESULTS: IL-8 and IL-8 receptors were expressed in all types of tumours with variable intensity and subcellular distribution. There was a statistically significant correlation between levels of expression and tumour stage and tumour type, being mostly significant in serous tumours. No correlation with patient progression free survival or overall survival was found.
CONCLUSION: This is the first study investigating the expression of IL-8 and IL-8 receptors using immunohistochemistry in different types of ovarian tumours, including benign and borderline tumours. IL-8 and IL-8RA are potential prognostic biomarkers and therapeutic targets in ovarian cancer, particularly in ovarian serous carcinoma.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; CCC; EC; IL-8; Interleukin-8; Interleukin-8 receptors; MC; OVCA; Ovarian; SC; Tumours; clear cell carcinoma; endometrial carcinoma; interleukin-8; mucinous carcinoma; ovarian carcinoma; serous carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23727325     DOI: 10.1016/j.cyto.2013.05.006

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  13 in total

1.  Positive association between Interleukin-8 -251A > T polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis.

Authors:  Daye Cheng; Yiwen Hao; Wenling Zhou; Yiran Ma
Journal:  Cancer Cell Int       Date:  2013-10-22       Impact factor: 5.722

2.  Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions.

Authors:  Anita Monika Chudecka-Głaz; Aneta Alicja Cymbaluk-Płoska; Janusz Leszek Menkiszak; Ewa Pius-Sadowska; Bogusław Bronisław Machaliński; Agnieszka Sompolska-Rzechuła; Izabella Anna Rzepka-Górska
Journal:  Onco Targets Ther       Date:  2015-02-23       Impact factor: 4.147

3.  Urinary interleukin-1β levels among gynecological patients.

Authors:  Kamisha T Woolery; Mitchel S Hoffman; Joshua Kraft; Santo V Nicosia; Ambuj Kumar; Patricia A Kruk
Journal:  J Ovarian Res       Date:  2014-11-18       Impact factor: 4.234

4.  Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein.

Authors:  Alexandria B Tino; Kenny Chitcholtan; Peter H Sykes; Ashley Garrill
Journal:  J Ovarian Res       Date:  2016-12-01       Impact factor: 4.234

5.  Actinomyosin contraction, phosphorylation of VE-cadherin, and actin remodeling enable melanoma-induced endothelial cell-cell junction disassembly.

Authors:  Eric Weidert; Steven E Pohler; Esther W Gomez; Cheng Dong
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

6.  Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors:  R E Kast
Journal:  Springerplus       Date:  2015-10-23

7.  The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.

Authors:  Euan A Stronach; Paula Cunnea; Christina Turner; Tankut Guney; Radhika Aiyappa; Senthuran Jeyapalan; Camila H de Sousa; Alacoque Browne; Nesreen Magdy; James B Studd; Ruethairat Sriraksa; Hani Gabra; Mona El-Bahrawy
Journal:  Oncotarget       Date:  2015-10-13

8.  Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.

Authors:  D S Matassa; M R Amoroso; H Lu; R Avolio; D Arzeni; C Procaccini; D Faicchia; F Maddalena; V Simeon; I Agliarulo; E Zanini; C Mazzoccoli; C Recchi; E Stronach; G Marone; H Gabra; G Matarese; M Landriscina; F Esposito
Journal:  Cell Death Differ       Date:  2016-05-20       Impact factor: 15.828

9.  Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors.

Authors:  Augustin Le Naour; Mélissa Prat; Benoît Thibault; Renaud Mével; Léa Lemaitre; Hélène Leray; Marie-Véronique Joubert; Kimberley Coulson; Muriel Golzio; Lise Lefevre; Eliane Mery; Alejandra Martinez; Gwénaël Ferron; Jean-Pierre Delord; Agnès Coste; Bettina Couderc
Journal:  J Mol Cell Biol       Date:  2020-04-24       Impact factor: 6.216

10.  IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer.

Authors:  Jirui Wen; Zhiwei Zhao; Liwei Huang; Ling Wang; Yali Miao; Jiang Wu
Journal:  J Cell Mol Med       Date:  2019-12-02       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.